Will AstraZeneca’s new strategy make the share price soar?

A pivot to cancer treatment has been profitable for AstraZeneca plc (LON:AZN), but can it last?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shareholders of AstraZeneca (LSE: AZN) have been on a bumpy ride these last six months, with the stock price bouncing between the 5,000p and 6,500p marks. Back in February, the company reported excellent operating results for the fourth quarter of the previous year, showing robust sales growth and earnings that exceeded analyst expectations.

However, since topping out in late March, shares are down more than 10%. Is this an opportunity for investors to get in on a pullback? Let’s dive into it.

Bestselling cancer drugs driving sales

Over the last few years, AstraZeneca has been increasingly focused on developing its oncology pipeline. Most notably, lung cancer drug Tagrisso has the potential to achieve blockbuster status. It has already become AstraZeneca’s best-selling drug, constituting 9% of total product sales at around £1.4 billion in 2018. Moreover, the drug is still a long way away from patent expiry, and some analysts believe that sales could peak at £4.5 billion in 2023. Even if sales fall short of that lofty figure – management’s own number is closer to £2.3 billion – Tagrisso is likely to be a reliable revenue source for AstraZeneca for years going forward.

A long-term strategy

CEO Pascal Soriot deserves a lot of credit for this turnaround. Appointed in 2012, following years of declining sales resulting from a steep patent cliff, he has managed to pivot AstraZeneca towards oncology treatments. This makes sense on two levels. Firstly, given the overall demographic trend of populations getting older, the prevalence of cancer is set to increase. Accordingly, pharmaceutical companies that reposition themselves to cater to this aging world will do comparatively well.

Secondly, AstraZeneca suffered a competitive disadvantage in that many of its older therapies were small-molecule, orally administered drugs that were quite easy to replicate. As a result, the company was hit hard by sales of generics almost as soon as those patents expired. While the conventional view is that patent expiry affects drug company equally, the reality is that makers of generics and biosimilars still need to manufacture the actual product, and so not all generics can undercut prices in the same way.

It’s a tough environment to live in

However, the current regulatory environment has thrown up a number of potential threats to AstraZeneca’s long-term prospects. In particular, the Food and Drug Administration in the USA is increasingly seen to favour lower-cost alternatives to some of the more expensive options. For instance, techniques such as gene editing are being looked at as potentially more cost-effective ways of treating cancer.

Although these technologies are still in relatively early stages, when one considers the fact that drug development takes place over a timescale of decades, it doesn’t seem like such a far-fetched threat. For this reason, I believe AstraZeneca could be vulnerable in the long run.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan does not own shares in AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »